Ron T. Gansevoort
A5005549802- Chronic Kidney Disease and Diabetes
- Dialysis and Renal Disease Management
- Genetic and Kidney Cyst Diseases
- Blood Pressure and Hypertension Studies
- Renal Diseases and Glomerulopathies
- Biomedical Research and Pathophysiology
- Diabetes Treatment and Management
- COVID-19 Clinical Research Studies
- Renal and related cancers
- Liver Disease Diagnosis and Treatment
- Heart Failure Treatment and Management
- Sodium Intake and Health
- Electrolyte and hormonal disorders
- Ion Transport and Channel Regulation
- Genetic Syndromes and Imprinting
- SARS-CoV-2 and COVID-19 Research
- Cardiovascular Function and Risk Factors
- Nutritional Studies and Diet
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Genetic Associations and Epidemiology
- Renal and Vascular Pathologies
- Health Systems, Economic Evaluations, Quality of Life
- Pediatric Urology and Nephrology Studies
- Birth, Development, and Health
- Parathyroid Disorders and Treatments
University Medical Center Groningen
2016-2025
University of Groningen
2016-2025
Erasmus MC
2006-2024
Erasmus MC Transplant Institute
2024
Bayer (Germany)
2024
University of Zurich
2023
Clinical Research Consortium
2021-2023
Pediatric Nephrology of Alabama
2006-2023
Target (United States)
2023
RELX Group (Netherlands)
2021-2023
The course of autosomal dominant polycystic kidney disease (ADPKD) is often associated with pain, hypertension, and failure. Preclinical studies indicated that vasopressin V2-receptor antagonists inhibit cyst growth slow the decline function.
Abstract Aims The aim of this study was to develop, validate, and illustrate an updated prediction model (SCORE2) estimate 10-year fatal non-fatal cardiovascular disease (CVD) risk in individuals without previous CVD or diabetes aged 40–69 years Europe. Methods results We derived models using individual-participant data from 45 cohorts 13 countries (677 684 individuals, 30 121 events). used sex-specific competing risk-adjusted models, including age, smoking status, systolic blood pressure,...
To help adapt cardiovascular disease risk prediction approaches to low-income and middle-income countries, WHO has convened an effort develop, evaluate, illustrate revised models. Here, we report the derivation, validation, illustration of charts that have been adapted circumstances 21 global regions.
Tolerability Study-Diabetic Nephropathy (ARTS-DN) Study Group IMPORTANCE Steroidal mineralocorticoid receptor antagonists, when added to a renin-angiotensin system blocker, further reduce proteinuria in patients with chronic kidney disease but may be underused because of high risk adverse events.OBJECTIVE To evaluate the safety and efficacy different oral doses nonsteroidal antagonist finerenone, given for 90 days diabetes or very albuminuria who are receiving an angiotensin-converting...
Differences in clinical characteristics and outcome of patients with established heart failure preserved ejection fraction (HFpEF) reduced (HFrEF) are well established. Data on epidemiology prediction new onset HFpEF, compared HFrEF, have not been described. In 8592 subjects the Prevention Renal Vascular End-stage Disease (PREVEND), a community-based, middle-aged cohort study, we performed cause-specific hazard analyses to study predictive value risk factors cardiovascular biomarkers HFrEF...
The worldwide burden of kidney disease is rising, but public awareness remains limited, underscoring the need for more effective communication by stakeholders in health community. Despite this clarity, nomenclature describing function and lacks uniformity. In June 2019, Kidney Disease: Improving Global Outcomes (KDIGO) convened a Consensus Conference with goal standardizing refining used English language to describe disease, developing glossary that could be scientific publications. Guiding...
In a previous trial involving patients with early autosomal dominant polycystic kidney disease (ADPKD; estimated creatinine clearance, ≥60 ml per minute), the vasopressin V2-receptor antagonist tolvaptan slowed growth in total volume and decline glomerular filtration rate (GFR) but also caused more elevations aminotransferase bilirubin levels. The efficacy safety of later-stage ADPKD are unknown.We conducted phase 3, randomized withdrawal, multicenter, placebo-controlled, double-blind trial....
CKD prevalence estimation is central to management and prevention planning at the population level. This study estimated in European adult general investigated international variation by age, sex, presence of diabetes, hypertension, obesity. We collected data from 19 general-population studies 13 countries. stages 1–5 was defined as eGFR<60 ml/min per 1.73 m 2 , calculated CKD-Epidemiology Collaboration equation, or albuminuria >30 mg/g, 3–5 . age- sex-standardized 27 Member States...